MSI1 and cancer: From this point of view, MSI1 solidifies its proposed role as a promising target candidate for cancer therapy, potentially as part of a combination therapy in a set of strategies, including differentiation therapy, Notch/Wnt antagonists and CDK or PARP inhibitors.